LIVE WEBINAR: Friday, December 4, 2020, 8:30 AM – 10:00 AM Pacific Time (11:30 AM – 1:00 PM Eastern Time)

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Multiple Myeloma (Part 1 of a 4-Part Series)

A Friday Satellite Symposia Live Webinar Series Preceding the 62nd ASH Annual Meeting

Faculty

Rafael Fonseca, MD
Getz Family Professor of Cancer
Director for Innovation and Transformational Relationships
Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
Chair, Department of Internal Medicine
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts



Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Edward A Stadtmauer, MD
Professor of Medicine
Leader, Hematologic Malignancies Program
Director, Bone Marrow and Stem Cell Transplant Program
Division of Hematology-Oncology
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Oncopeptides, Sanofi Genzyme and Takeda Oncology.

Friday, December 4, 2020
8:30 AM – 10:00 AM PT (11:30 AM – 1:00 PM ET)
Live CME-accredited webinar

Topics to Be Discussed

  • Optimizing Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)
  • Prolonging Benefit with Effective Consolidation and Maintenance Regimens for Newly Diagnosed MM
  • Selection and Sequencing of Therapies for Patients with Relapsed/Refractory MM
  • Chimeric Antigen Receptor T-Cell Therapy and Other Strategies Targeting B-Cell Maturation Antigen
  • Other Novel Strategies with Potential to Improve Outcomes in MM
A detailed agenda will be provided by November.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Design and implement a plan of care for patients with smoldering MM, considering the applicability of existing and emerging clinical trial data.
  • Customize the use of induction, consolidation and maintenance therapeutic approaches for MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Appreciate available clinical trial data documenting the efficacy of monoclonal antibody therapy directed at CD38 as a component of induction therapy, and effectively identify whether and how this strategy should be integrated into the clinical care of patients eligible or ineligible for stem cell transplant.
  • Recognize published research data validating the use of minimal residual disease (MRD) status as a mechanism to assess response to active therapy and to identify disease recurrence, and use this information to determine the potential role of MRD assays in the protocol and off-protocol management of MM.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combination of available therapies in the nonresearch care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanism of action of and available data with recently FDA-approved novel therapies to facilitate their integration into MM management algorithms.
  • Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target B-cell maturation antigen, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches as part of clinical trials.
  • Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other investigational approaches for MM, and consider the potential role of these therapies in clinical practice.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Oncopeptides, Sanofi Genzyme and Takeda Oncology.